LEO Pharma secures global rights to JW1601 in $402m deal with JW Pharmaceutical
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant deal valued at approximately KRW 450 billion ($402 million). This licensing agreement, however, excludes South Korea, where JWP will retain exclusive rights. Under the terms of the agreement, LEO Pharma […]